AnserBio
Nanoparticle based delivery of p53 protein - addressing the most frequent mutation in cancer. -
Company Overview
Snapshot
Founded in January 2017 by Lana Volokh and Dr. Alex Tendler, AnserBio operates with 1–10 employees. The company has raised $6.45 million across 6 funding rounds from 3 investors. In December 2023, AnserBio secured a Seed funding round.
Business overview
AnserBio, formerly ExoProTher Medical, is a biomedical startup focused on developing a novel approach to cancer treatment. The company utilizes proprietary cell-derived nanoparticles to deliver healthy p53 protein, aiming to restore the body's natural tumor suppression function. This technology targets p53-based tumor suppression mechanisms, which are mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. AnserBio operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, with its technology rooted in nanotechnology and cell biology, and is currently in the preclinical stage.
Strategic signal
In January 2021, AnserBio's innovative approach to cancer treatment was highlighted in an article titled 'Fighting cancer from within'. This news signals the company's early recognition for its potential to address a significant unmet medical need by targeting the p53 tumor suppression mechanism, which is frequently mutated in various cancers. For investors, this indicates validation of AnserBio's scientific premise and potential for future development in the oncology space.
Company Intelligence Q&A
- What is AnserBio's primary focus in cancer treatment?
- AnserBio focuses on developing a novel approach to cancer treatment by targeting the p53-based tumor suppression mechanism, which is mutated in over 60% of cancers. The company uses proprietary cell-derived nanoparticles to deliver healthy p53 protein and restore natural tumor suppression.
- When was AnserBio founded and by whom?
- AnserBio was founded in January 2017 by Lana Volokh and Dr. Alex Tendler.
- What was a key funding event for AnserBio in 2023?
- In December 2023, AnserBio secured a Seed funding round. Prior to this, in July 2023, Peregrine Ventures participated in a SAFE funding round.
- Which investor participated in AnserBio's SAFE funding rounds in 2022 and 2023?
- Peregrine Ventures participated in SAFE funding rounds for AnserBio in November 2022 and July 2023.
- What is the current development stage of AnserBio's cancer treatment?
- AnserBio's cancer treatment approach is currently in the preclinical stage.